Looking for value?
OriBase Pharma is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.
OriBase Pharma as an investment case
OriBase Pharma is an innovative European R&D-based pharmaceutical company with a special emphasis on developing medicinal treatments for aggressive cancers. OriBase Pharma discovers and develops active anticancer drug candidates up to phase II. OriBase Pharma’s customers are mainly pharmaceutical companies.
The objective of OriBase Pharma’s intensive research is to bring new innovative patented proprietary drugs to pharmaceutical companies for international markets. OriBase Pharma’s pharmaceutical R&D focuses on oncology indications such as:
- Liver cancer
- Pancreatic cancer
- Triple Negative Breast cancer
- Lung Cancer
The present OriBase Pharma Corporation started operations on 13 September 2007.
Reasons to invest
- Unique platform - faster time for discovery & early development
- Potential First-in-class and Best-in-class drugs
- Balanced portfolio of compounds with several possible indications
- Protective IP strategy
- Very limited treatments for resistant human cancers - Unmet medical need
- Growing markets worth 1 to 2 billion $
- Experienced and committed Management team